Long term extension study for gotistobart treated patients
Part of Cancer clinical trials.
This study is for people who have already been taking the drug gotistobart in a previous trial. It allows them to keep receiving the drug for a longer time, so doctors can see how the treatment works over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and agree to take part in the study.
- You have been diagnosed with advanced solid tumor cancer that cannot be removed by surgery or has spread.
- You are currently in a qualifying study called PRESERVE-100 and are being treated with gotistobart, either alone or with other drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
This study tests a new drug (SYS6006) combined with an existing immunotherapy (called Enlonstobart) to see if it works better than the immunotherapy alone for people with advanced solid tumors. It may help shrink or slow the growth of your cancer.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.